SAB Biotherapeutics, Inc. (SABS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, SAB Biotherapeutics reported revenue of $0, down 100.0% from $1.3M the year before. Net income was $13.3M, or -$0.79 per diluted share. Operating activities generated -$44.8M of cash, leaving -$45.7M of free cash flow. At fiscal year end, SAB Biotherapeutics held $172.8M in total assets against $21.3M in total liabilities, including $10.5M of cash and equivalents.
Open the full interactive SAB Biotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
SAB Biotherapeutics Key Stats
| Share Price | $2.68 |
|---|---|
| Market Cap | $213.7M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $2.17 – $4.59 |
| Shares Outstanding | 79.8 million (basic, 2026 Q2) |
SAB Biotherapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $60.9M | $23.9M | $2.2M | $1.3M | $0 |
| Operating Income | -$13.4M | -$28.9M | -$38.1M | -$42.9M | -$49.0M |
| Pre-Tax Income | -$17.1M | -$18.7M | -$42.2M | -$34.1M | $13.3M |
| Income Tax | $0 | $25,629 | $0 | $0 | $0 |
| Net Income | -$17.1M | -$18.7M | -$42.2M | -$34.1M | $13.3M |
| Diluted EPS | -$6.30 | — | -$7.64 | -$3.68 | -$0.79 |
SAB Biotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | $45.4M | -$16.9M | -$18.9M | -$22.5M |
| Diluted EPS | -$0.21 | -$0.27 | -$0.35 | -$0.28 |
SAB Biotherapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $33.2M | $15.0M | $56.6M | $8.9M | $10.5M |
| Current Assets | $48.4M | $22.1M | $58.9M | $23.8M | $101.1M |
| Total Assets | $79.4M | $50.9M | $83.9M | $44.2M | $172.8M |
| Current Liabilities | $24.7M | $15.0M | $10.8M | $8.0M | $10.7M |
| Total Long-Term Debt | — | $1.3M | — | — | — |
| Total Liabilities | $40.8M | $19.8M | $26.6M | $18.2M | $21.3M |
| Shareholders' Equity | $38.5M | $31.1M | $57.3M | $26.0M | $151.5M |
SAB Biotherapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | $3.8M | -$23.5M | -$25.1M | -$34.3M | -$44.8M |
| Cash From Investing | -$10.9M | -$2.1M | -$152,704 | -$12.0M | -$121.7M |
| Cash From Financing | $34.1M | $1.1M | $66.8M | -$1.2M | $168.3M |
| Free Cash Flow | -$7.2M | -$25.6M | -$25.3M | -$34.6M | -$45.7M |
Figures from SAB Biotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full SAB Biotherapeutics financials page for every line item.
SAB Biotherapeutics Company Profile
| Ticker | SABS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Miami Beach, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001833214 |
Frequently Asked Questions
What was SAB Biotherapeutics' revenue in fiscal 2025?
SAB Biotherapeutics (SABS) reported revenue of $0 for fiscal 2025.
What is SAB Biotherapeutics' annual revenue history?
SAB Biotherapeutics' annual revenue by fiscal year: 2021: $60.9M; 2022: $23.9M; 2023: $2.2M; 2024: $1.3M; 2025: $0.
What was SAB Biotherapeutics' net income in fiscal 2025?
SAB Biotherapeutics reported net income of $13.3M for fiscal 2025.
What was SAB Biotherapeutics' earnings per share (EPS) in fiscal 2025?
SAB Biotherapeutics' diluted EPS was -$0.79 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did SAB Biotherapeutics generate in fiscal 2025?
SAB Biotherapeutics generated -$45.7M of free cash flow in fiscal 2025.
What was SAB Biotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), SAB Biotherapeutics reported revenue of $0.
How many shares of SAB Biotherapeutics are outstanding?
SAB Biotherapeutics reported a weighted average of 79.8 million basic shares outstanding in 2026 Q2.
What is SAB Biotherapeutics' market cap?
Based on its latest closing price, SAB Biotherapeutics (SABS) has a market capitalization of about $213.7M.
When does SAB Biotherapeutics' fiscal year end?
SAB Biotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is SAB Biotherapeutics headquartered?
SAB Biotherapeutics lists its business address in Miami Beach, Florida in its SEC filings.
SAB Biotherapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →